References
- Bargou RC, Wagener C, Bommert K, et al (1996). Overexpression of the death-promoting gene Bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest, 97, 2651-9. https://doi.org/10.1172/JCI118715
- Carrick S, Parker S, Thornton CE, et al (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, 2, 3372.
- Childs AC, Phaneuf SL, Dirks AJ, et al (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res, 62, 4592-8.
- Chinnaiyan AM (1999). The apoptosome: heart and soul of the cell death machine. Neoplasia, 1, 5-15. https://doi.org/10.1038/sj.neo.7900003
- Chipuk JE, Bouchier-Hayes L and Green DR (2006). Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ, 13, 1396-402. https://doi.org/10.1038/sj.cdd.4401963
- Chipuk JE, Moldoveanu T, Llambi F, et al (2010). The Bcl-2 family reunion. Mol Cell, 37, 299-310. https://doi.org/10.1016/j.molcel.2010.01.025
- Coley HM (2004). Development of drug-resistant models. Methods Mol Med, 88, 267-73.
- Crawford A and Nahta R (2011). Targeting Bcl-2 in herceptinresistant breast cancer cell lines. Curr Pharmacogenomics Person Med, 9, 184-90. https://doi.org/10.2174/187569211796957584
- Crotzer DR, Sun CC, Coleman RL, et al (2007). Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol, 105, 404-8. https://doi.org/10.1016/j.ygyno.2006.12.024
- Cryns V and Yuan J (1998). Proteases to die for. Genes Dev, 12, 1551-70. https://doi.org/10.1101/gad.12.11.1551
- Danial NN and Korsmeyer SJ (2004). Cell death: critical control points. Cell, 116, 205-19. https://doi.org/10.1016/S0092-8674(04)00046-7
- Darakhshan S, Bidmeshkipour A, Khazaei M, et al (2013). Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. Asian Pac J Cancer Prev, 14, 6869-74. https://doi.org/10.7314/APJCP.2013.14.11.6869
- Degterev A, Boyce M and Yuan J (2003). A decade of caspases. Oncogene, 22, 8543-67. https://doi.org/10.1038/sj.onc.1207107
- Ferreira KS, Kreutz C, Macnelly S, et al (2012). Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis, 17, 503-15. https://doi.org/10.1007/s10495-011-0691-0
- Fulda S, Debatin KM (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene, 25, 4798-811. https://doi.org/10.1038/sj.onc.1209608
- Gabizon A, Papahadjopoulos D (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA, 85, 6949-53. https://doi.org/10.1073/pnas.85.18.6949
- Gabizon A, Price DC, Huberty J, et al (1990). Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res, 50, 6371-8.
- Gabizon AA (1992). Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in longcirculating liposomes. Cancer Res, 52, 891-6.
- Garcia M, Jemal A, Ward E, et al (2007). Global cancer facts & figures 2007. Atlanta, GA: American cancer society, 1.
- Gee JM, Robertson JF, Ellis IO, et al (1994). Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer, 59, 619-28. https://doi.org/10.1002/ijc.2910590508
- Ghanbari P, Mohseni M, Tabasinezhad M, et al (2014). Inhibition of survivin restores the sensitivity of breast cancer cells to docetaxel and vinblastine. Appl Biochem Biotechnol, 174, 667-81. https://doi.org/10.1007/s12010-014-1125-6
- Ghafouri-Fard S, Abdollahi DZ, Omrani M, et al (2012). shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDA-MB-231 cell lines. Asian Pac J Cancer Prev, 13, 5865-9. https://doi.org/10.7314/APJCP.2012.13.11.5865
- Hamedeyazdan S, Fathiazad F, Sharifi S, et al (2012). Antiproliferative activity of Marrubium persicum extract in the MCF-7 human breast cancer cell line. Asian Pac J Cancer Prev, 13, 5843-8. https://doi.org/10.7314/APJCP.2012.13.11.5843
- Hembruff SL, Laberge ML, Villeneuve DJ, et al (2008). Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer, 8, 318. https://doi.org/10.1186/1471-2407-8-318
- Iseri OD, Kars MD, Arpaci F, et al (2010). Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol, 65, 447-55. https://doi.org/10.1007/s00280-009-1048-z
- Janicke RU, Sprengart ML, Wati MR, et al (1998). Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem, 273, 9357-60. https://doi.org/10.1074/jbc.273.16.9357
- Kelly PN and Strasser A (2011). The role of Bcl-2 and its prosurvival relatives in tumourigenesis and cancer therapy. Cell Death Differ, 18, 1414-24. https://doi.org/10.1038/cdd.2011.17
- Leung LK and Wang TT (1999). Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat, 55, 73-83. https://doi.org/10.1023/A:1006190802590
- Lindsay J, Esposti MD and Gilmore AP (2011). Bcl-2 proteins and mitochondria--specificity in membrane targeting for death. Biochim Biophys Acta, 1813, 532-9. https://doi.org/10.1016/j.bbamcr.2010.10.017
- McDermott M, Eustace AJ, Busschots S, et al (2014). In vitro development of chemotherapy and targeted therapy drugresistant cancer cell lines: a practical guide with case studies. Front Oncol, 4, 40.
- Moulder S, Hortobagyi GN (2008). Advances in the treatment of breast cancer. Clin Pharmacol Ther, 83, 26-36. https://doi.org/10.1038/sj.clpt.6100449
- Ola MS, Nawaz M and Ahsan H (2011). Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem, 351, 41-58. https://doi.org/10.1007/s11010-010-0709-x
- Olsson M and Zhivotovsky B (2011). Caspases and cancer. Cell Death Differ, 18, 1441-9. https://doi.org/10.1038/cdd.2011.30
- Oltvai ZN, Milliman CL and Korsmeyer SJ (1993). Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74, 609-19. https://doi.org/10.1016/0092-8674(93)90509-O
- Ouyang L, Shi Z, Zhao S, et al (2012). Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif, 45, 487-98. https://doi.org/10.1111/j.1365-2184.2012.00845.x
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Piche A, Grim J, Rancourt C, et al (1998). Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line MCF-7. Cancer Res, 58, 2134-40.
- Pommier Y, Sordet O, Antony S, et al (2004). Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene, 23, 2934-49. https://doi.org/10.1038/sj.onc.1207515
- Rastogi RP, Sinha RP (2009). Apoptosis: molecular mechanisms and pathogenicity. EXCLI J, 8, 155-81.
- Reed JC (1998). Bcl-2 family proteins. Oncogene, 17, 3225-36.
- Ring AE and Ellis PA (2005). Taxanes in the treatment of early breast cancer. Cancer Treat Rev, 31, 618-27. https://doi.org/10.1016/j.ctrv.2005.09.005
- Sabzichi M, Hamishehkar H, Ramezani F, et al. (2014). Luteolinloaded phytosomes sensitize human breast carcinoma MDAMB 231 cells to doxorubicin by suppressing Nrf2 mediated signalling. Asian Pac J Cancer Prev, 15, 5311-6. https://doi.org/10.7314/APJCP.2014.15.13.5311
- Saloustros E, Mavroudis D, Georgoulias V (2008). Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother, 9, 2603-16. https://doi.org/10.1517/14656566.9.15.2603
- Scaffidi C, Fulda S, Srinivasan A, et al (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 17, 1675-87. https://doi.org/10.1093/emboj/17.6.1675
- Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, et al (2006). Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res, 12, 7054-8. https://doi.org/10.1158/1078-0432.CCR-06-0950
- Seifi-Alan M, Shamsi R, Ghafouri-Fard S, et al (2013). Expression analysis of two cancer-testis genes, FBXO39 and TDRD4, in breast cancer tissues and cell lines. Asian Pac J Cancer Prev, 14, 6625-9. https://doi.org/10.7314/APJCP.2013.14.11.6625
- Seve P, Isaac S, Tredan O, et al (2005). Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res, 11, 5481-6. https://doi.org/10.1158/1078-0432.CCR-05-0285
- Shajahan AN, Dobbin ZC, Hickman FE, et al (2012). Tyrosinephosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem, 287, 17682-92. https://doi.org/10.1074/jbc.M111.304022
- Simstein R, Burow M, Parker A, et al (2003). Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood), 228, 995-1003.
- Stoetzer OJ, Nussler V, Darsow M, et al (1996). Association of Bcl-2, Bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. Leukemia, 10, 18-22.
- Strasser A, Harris AW, Huang DC, et al (1995). Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J, 14, 6136-47.
- Tabasinezhad M, Samadi N, Ghanbari P, et al (2013). Sphingosin 1-phosphate contributes in tumor progression. J Cancer Res Ther, 9, 556-63. https://doi.org/10.4103/0973-1482.126446
- Tang D, Lahti JM, Kidd VJ (2000). Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem, 275, 9303-7. https://doi.org/10.1074/jbc.275.13.9303
- Thornberry NA, Lazebnik Y (1998). Caspases: enemies within. Science, 281, 1312-6. https://doi.org/10.1126/science.281.5381.1312
- Wang H, Vo T, Hajar A, et al (2014). Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. BMC Cancer, 14, 37. https://doi.org/10.1186/1471-2407-14-37
- Ward S, Simpson E, Davis S, et al (2007). Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess, 11, 1-144.
- Wild PJ, Reichle A, Andreesen R, et al (2004). Microsatellite instability predicts poor short-term survival in patients with advanced breast cancer after high-dose chemotherapy and autologous stem-cell transplantation. Clin Cancer Res, 10, 556-64. https://doi.org/10.1158/1078-0432.CCR-0601-03
- Yang E and Korsmeyer SJ (1996). Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88, 386-401.
- Zuo KQ, Zhang XP, Zou J, et al (2010). Establishment of a paclitaxel resistant human breast cancer cell strain (MCF-7/Taxol) and intracellular paclitaxel binding protein analysis. J Int Med Res, 38, 1428-35. https://doi.org/10.1177/147323001003800424
Cited by
- Cerebrospinal fluid from rats given hypoxic preconditioning protects neurons from oxygen-glucose deprivation-induced injury vol.10, pp.9, 2015, https://doi.org/10.4103/1673-5374.165519
- β-elemene Induces Caspase-dependent Apoptosis in Human Glioma Cells in vitro through the Upregulation of Bax and Fas/FasL and Downregulation of Bcl-2 vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10407
- Arsenic Trioxide Promotes Paclitaxel Cytotoxicity in Resistant Breast Cancer Cells vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5191
- Nuclear DNA Damage and Repair in Normal Ovarian Cells Caused by Epothilone B vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6535
- Silibilin-Induces Apoptosis in Breast Cancer Cells by Modulating p53, p21, Bak and Bcl-xl Pathways vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2087
- Direct Activation of Bax Protein for Cancer Therapy vol.36, pp.2, 2015, https://doi.org/10.1002/med.21379
- Hyperoside protects human primary melanocytes against H2O2-induced oxidative damage vol.13, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5107
- Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy vol.16, pp.1, 2016, https://doi.org/10.1186/s12935-016-0290-9
- SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway vol.25, pp.3, 2017, https://doi.org/10.1080/1061186X.2016.1245307
- Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy vol.55, pp.1, 2017, https://doi.org/10.1080/13880209.2016.1270972
- Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion vol.6, pp.2046-1402, 2017, https://doi.org/10.12688/f1000research.10992.1
- Reactive Oxygen Species Are Necessary for Bleomycin A5-Induced Apoptosis and Extracellular Matrix Elimination of Nasal Polyp-Derived Fibroblasts pp.1943-572X, 2018, https://doi.org/10.1177/0003489418812905
- Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles pp.1029-2330, 2018, https://doi.org/10.1080/1061186X.2018.1491978